Successful cord blood transplantation for a paroxysmal nocturnal hemoglobinuria complicated with Budd-Chiari syndrome and myelodysplastic syndrome

  • Taro TakahashiEmail author
  • Satoshi Ichikawa
  • Hideo Harigae
Letter to the Editor



We thank all medical and nurse personnel of the Osaki Citizen Hospital for dedicated work.

Compliance with ethical standards

All the authors have read the manuscript and have approved this submission.

The patient has provided permission to publish these features of his case, and the identity of the patient has been protected.

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in this report were in accordance with the ethical standards of the institutional and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.


  1. 1.
    Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV (1995) Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 333:1253–1258CrossRefGoogle Scholar
  2. 2.
    Matos-Fernandez NA, Yasser R et al (2009) Current status of allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Transplant 15:656–661CrossRefGoogle Scholar
  3. 3.
    Hillmen P, Muus P, Duhrsen U, Risitano AM, Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill A, Socie G, Bessler M, Rollins SA, Bell L, Rother RP, Young NS (2007) Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 110:4123–4128CrossRefGoogle Scholar
  4. 4.
    Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, Mitchell LD, Cohen DR, Gregory WM, Hillmen P (2011) Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117:6786–6792CrossRefGoogle Scholar
  5. 5.
    Cooper JP, Farah RJ, Stevenson PA, Gooley TA, Storb R, Scott BL (2019) Hematopoietic cell transplantation for paroxysmal nocturnal hemoglobinuria in the age of eculizumab. Biol Blood Marrow Transplant 25:1331–1339CrossRefGoogle Scholar
  6. 6.
    Saso R, Marsh J, Cevreska L, Szer J, Gale RP, Rowlings P, Passweg J, Nugent M, Luzzatto L, Horowitz M, Gordon-Smith E (1999) Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol 104:392–396CrossRefGoogle Scholar
  7. 7.
    de Latour RP, Schrezenmeier H, Bacigalupo A, Blaise D, de Souza CA, Vigouroux S, Willemze R, Terriou L, Tichelli A, Mohty M, de Guibert S, Marsh JC, Passweg J, Yves Mary J, Socie G (2012) Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica 97:1666–1673CrossRefGoogle Scholar
  8. 8.
    Pantin J, Tian X, Geller N, Ramos C, Cook L, Cho E, Scheinberg P, Vasu S, Khuu H, Stroncek D, Barrett J, Young NS, Donohue T, Childs RW (2014) Long-term outcome of fludarabine-based reduced-intensity allogeneic hematopoietic cell transplantation for debilitating paroxysmal nocturnal hemoglobinuria. Biol Blood Marrow Transplant 20:1435–1454CrossRefGoogle Scholar
  9. 9.
    Yamamoto H, Uchida N, Yuasa M, Kageyama K, Ota H, Kaji D, Nishida A, Ishiwata K, Takagi S, Tsuji M, Asano-Mori Y, Yamamoto G, Izutsu K, Masuoka K, Wake A, Yoneyama A, Makino S, Taniguchi S (2016) A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood transplantation provides durable engraftment and remission in nonremission myeloid malignancies. Biol Blood Marrow Transplant 22:1844–1850CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of HematologyOsaki Citizen HospitalOsaki-shiJapan
  2. 2.Department of Hematology and RheumatologyTohoku University Graduate School of MedicineSendaiJapan

Personalised recommendations